5043-81-2

Basic information

• Product Name: Methyl 3-amino-5-chloro-2-hydroxybenzoate
• Synonyms: 3-AMINO-5-CHLORO-2-HYDROXYBENZOIC ACID METHYL ESTER;methyl 3-amino-5-chloro-2-hydroxybenzoate;Methyl 3-amino-5-chlorosalicylate;3-AMINO-5-CHLORO-2-HYDROXYBENZOIC ACID ME ESTER;3-amino-5-chloro-2-hydroxybenzoate;SALICYLICACID,3-AMINO-5-CHLORO-,METHYLESTER(7CI,8CI);3-Amino-5-chloro-salicylic Acid Methyl Ester;methyl 3-amino-5-chloro-2-hydroxybenzoate hydrochloride
• CAS NO: 5043-81-2
• Molecular Formula: C₈H₈ClNO₃
• Molecular Weight: 201.61
• Product Categories: Benzoic acid;Amines;Aromatics;Intermediates
• Mol File: 5043-81-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 71-73°C
• Boiling Point: 322°C at 760 mmHg
• Flash Point: 148.5°C
• Appearance: /
• Density: 1.44g/cm³
• Vapor Pressure: 0.000153mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 9.11±0.23(Predicted)
• CAS DataBase Reference: Methyl 3-amino-5-chloro-2-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-amino-5-chloro-2-hydroxybenzoate(5043-81-2)
• EPA Substance Registry System: Methyl 3-amino-5-chloro-2-hydroxybenzoate(5043-81-2)

Safety Data

• Hazardous Substances Data: 5043-81-2(Hazardous Substances Data)

Usage

Chemical Properties

Light Brown Solid

InChI:InChI=1/C8H8ClNO3/c1-13-8(12)5-2-4(9)3-6(10)7(5)11/h2-3,11H,10H2,1H3

Upstream product

• 5043-79-8 5-chloro-2-hydroxy-3-nitrobenzoic acid methyl ester 
• 4068-78-4 methyl 5-chloro-2-hydroxybenzoate 

Downstream Products

• 873862-55-6 methyl 3-acetylamino-5-chlorosalicylate 
• 123040-16-4 Azasetron hydrochloride 
• 141761-83-3 6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxylic acid methyl ester 
• 141762-14-3 6-Chloro-3-oxo-4-phenethyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide 
• 141762-13-2 4-Benzyl-6-chloro-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide 
• 141762-06-3 6-Chloro-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-benzyl-piperidin-4-yl)-amide 
• 141762-05-2 6-Chloro-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-benzyl-piperidin-3-yl)-amide 
• 123040-69-7 azasetron 
• 141761-94-6 6-Chloro-3-oxo-4-phenethyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester 
• 141762-01-8 6-Chloro-3-oxo-4-phenethyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid 
• 141761-93-5 4-Benzyl-6-chloro-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester 
• 141762-00-7 4-Benzyl-6-chloro-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid 
• 123040-50-6 6-chloro-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazine-8-carboxylic acid chloride 
• 123040-79-9 6-chloro-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazine-8-carboxylic acid 

Relevant articles and documents

Synthesis method of azasetron hydrochloride intermediate methyl 3-amino-5-chloro-2-hydroxybenzoate

The invention discloses a synthesis method of azasetron hydrochloride intermediate methyl 3-amino-5-chloro-2-hydroxybenzoate, which comprises the following steps: (1) dissolving methyl 5-chloro-2-hydroxy-3-nitrobenzoate in ethanol, adding stannous chlorid

AMINO PYRAZOLONE DERIVATIVE HAVING CONDENSED RING STRUCTURE

PROBLEM TO BE SOLVED: To provide a compound that has excellent inhibitory action on ATPase activity of TIP48/TIP49 complex and is therefore useful for the treatment of tumor, or a pharmacologically acceptable salt thereof. SOLUTION: The present invention provides a compound having a structure represented by general formula (I), its pharmacologically acceptable salt, or a pharmaceutical composition comprising the compound (where R3, R4, R5, R6, R7, W, X, Y, and Z are as defined in the specifications). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain